Focus

merck

COVID News
COVID News

Study Links Merck’s COVID-19 Antiviral Pill to Mutated Strains

Study Links Merck’s COVID-19 Antiviral Pill to Mutated Strains
|
Companies
Companies

Top 5 US Pharma Companies Netted $82 Billion in 2022: Report

Top 5 US Pharma Companies Netted $82 Billion in 2022: Report
|
US News
US News

Johnson & Johnson Sues to Block Medicare Drug Price Negotiations

Johnson & Johnson Sues to Block Medicare Drug Price Negotiations
|
Health & Safety
Health & Safety

Merck Facing Lawsuits for Allegedly Hiding Severe Psychiatric Side Effects of Asthma Drug

Merck Facing Lawsuits for Allegedly Hiding Severe Psychiatric Side Effects of Asthma Drug
|
Executive Branch
Executive Branch

Merck Sues Biden Administration Over ‘Sham’ Drug Price Negotiation Program

Merck Sues Biden Administration Over ‘Sham’ Drug Price Negotiation Program
|
Frontline Health
Frontline Health

HPV Vaccine: Is It Even Worth It?

HPV Vaccine: Is It Even Worth It?
|
Companies
Companies

Merck’s COVID-19 Drug Fails to Show ‘Statistically Significant Reduction’ in Infection Risk

Merck’s COVID-19 Drug Fails to Show ‘Statistically Significant Reduction’ in Infection Risk
|
CCP Virus
CCP Virus

Researchers Link COVID-19 Drug to New Virus Mutations in Patients

Researchers Link COVID-19 Drug to New Virus Mutations in Patients
|
Companies
Companies

Merck Opts to Develop, Sell Cancer Vaccine With Moderna

Merck Opts to Develop, Sell Cancer Vaccine With Moderna
|
WORLD
WORLD

Merck’s Antiviral COVID-19 Pill Approved in Singapore

Merck’s Antiviral COVID-19 Pill Approved in Singapore
|
Businesses in COVID-19
Businesses in COVID-19

Merck Raises 2022 Forecast as COVID Pill, Cancer Drug Fuels Profit Beat

Merck Raises 2022 Forecast as COVID Pill, Cancer Drug Fuels Profit Beat
|
Chinese Regime
Chinese Regime

FDA Rejects Eli Lilly’s China-Developed Cancer Drug

FDA Rejects Eli Lilly’s China-Developed Cancer Drug
|
Businesses in COVID-19
Businesses in COVID-19

Merck Sees 2022 Sales up Nearly 20 Percent, Mostly on New COVID Pill

Merck Sees 2022 Sales up Nearly 20 Percent, Mostly on New COVID Pill
|
WORLD
WORLD

EU Approves Pfizer’s COVID-19 Pill for Adults at Risk of Severe Disease

EU Approves Pfizer’s COVID-19 Pill for Adults at Risk of Severe Disease
|
Vaccines & Safety
Vaccines & Safety

Researchers Concerned CCP Virus Will Develop Resistance to New Pfizer, Merck Pills

Researchers Concerned CCP Virus Will Develop Resistance to New Pfizer, Merck Pills
|
Companies
Companies

Merck Expects COVID-19 Pill Molnupiravir to Be Effective Against Omicron

Merck Expects COVID-19 Pill Molnupiravir to Be Effective Against Omicron
|
Companies
Companies

Italy to Receive 40,000 Merck Antiviral Drug Doses Next Week: Official

Italy to Receive 40,000 Merck Antiviral Drug Doses Next Week: Official
|
Facts Matter
Facts Matter

EpochTV: Rejects FDA Request, Gives Agency 8 Months to Produce Pfizer’s Safety Data

Facts Matter (Jan. 7): Rejects FDA Request, Gives Agency 8 Months to Produce Pfizer’s Safety Data
|
Vaccines & Safety
Vaccines & Safety

India Won’t Add Merck’s COVID-19 Pill to National Treatment Protocol, Citing Safety Concerns

India Won’t Add Merck’s COVID-19 Pill to National Treatment Protocol, Citing Safety Concerns
|
Businesses in COVID-19
Businesses in COVID-19

Merck Authorizes Indian Pharma Company to Manufacture and Supply Affordable COVID-19 Pills

Merck Authorizes Indian Pharma Company to Manufacture and Supply Affordable COVID-19 Pills
|